The development of an ex vivo regional gene therapy clinical pathway using adipose-derived stem cells (ASCs) may require cryopreservation for cell culture, storage, and transport prior to clinical use. ASCs isolated from five donors were transduced with a lentiviral vector containing BMP-2. Three groups were assessed: transduction without cell freezing (group 1), freezing of cells for 3 weeks followed by transduction (group 2), and cell transduction prior to freezing (group 3). Nontransduced cells were used as a control. The cluster of differentiation (CD) marker profiles, cell number, BMP-2 production, and osteogenic potential were measured. The CD marker profile (CD44, CD73, CD90, and CD105) was unchanged after cryopreservation. Cell number was equivalent among cryopreservation protocols in transduced and nontransduced cells. There was a trend toward decreased BMP-2 production in group 3 compared to groups 1 and 2. Osteogenic potential based on Alizarin red concentration was higher in group 2 compared to group 3, with no difference compared to group 1. Freezing ASCs prior to transduction with a lentiviral vector containing BMP-2 has no detrimental effect on cell number, BMP-2 production, osteogenic potential, or immunophenotype. Transduction prior to freezing, however, may limit the BMP-2 production and potential osteogenic differentiation of the ASCs.
Get full access to this article
View all access options for this article.
References
1.
RibeilJ-A, Hacein-Bey-AbinaS, PayenE, et al.Gene therapy in a patient with sickle cell disease. N Engl J Med, 2017; 376:848–855.
2.
HeierJS, KheraniS, DesaiS, et al.Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a Phase 1, open-label trial. Lancet, 2017; 390:50–61.
3.
SessaM, LorioliL, FumagalliF, et al.Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, Phase 1/2 trial. Lancet, 2016; 388:476–487.
4.
CastielloMC, ScaramuzzaS, PalaF, et al.B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott–Aldrich syndrome. J Allergy Clin Immunol, 2015; 136:692–702.e2.
5.
GruppSA, KalosM, BarrettD, et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 2013; 368:1509–1518.
6.
AlaeeF, BartholomaeC, SugiyamaO, et al.Biodistribution of LV-TSTA transduced rat bone marrow cells used for “ex-vivo” regional gene therapy for bone repair. Curr Gene Ther, 2015; 15:481–491.
7.
LiebermanJR, DaluiskiA, StevensonS, et al.The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am, 1999; 81:905–917.
8.
PittengerMF, MackayAM, BeckSC, et al.Multilineage potential of adult human mesenchymal stem cells. Science, 1999; 284:143–147.
9.
ZukPA, ZhuM, MizunoH, et al.Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng, 2001; 7:211–228.
LockeM, WindsorJ, DunbarPR. Human adipose-derived stem cells: isolation, characterization and applications in surgery. ANZ J Surg, 2009; 79:235–244.
12.
O'HalloranN, CourtneyD, KerinMJ, et al.Adipose-derived stem cells in novel approaches to breast reconstruction: their suitability for tissue engineering and oncological safety. Breast Cancer (Auckl), 2017; 11:1178223417726777.
13.
TajimaS, TobitaM, MizunoH. Current status of bone regeneration using adipose-derived stem cells. Histol Histopathol, 2018; 33:619–627.
14.
RouraS, Gálvez-MontónC, MirabelC, et al.Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?. Stem Cell Res Ther, 2017; 8:238.
15.
GimbleJM, GuilakF, BunnellBA. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther, 2010; 1:19.
16.
MantovaniC, TerenghiG, MagnaghiV. Senescence in adipose-derived stem cells and its implications in nerve regeneration. Neural Regen Res, 2014; 9:10–15.
17.
RoatoI, AlottoD, BelisarioDC, et al.Adipose derived-mesenchymal stem cells viability and differentiating features for orthopaedic reparative applications: banking of adipose tissue. Stem Cells Int, 2016; 2016:4968724.
18.
ChoudheryMS, BadowskiM, MuiseA, et al.Cryopreservation of whole adipose tissue for future use in regenerative medicine. J Surg Res, 2014; 187:24–35.
19.
MinonzioG, CorazzaM, MariottaL, et al.Frozen adipose-derived mesenchymal stem cells maintain high capability to grow and differentiate. Cryobiology, 2014; 69:211–216.
20.
Miyagi-ShiohiraC, KurimaK, KobayashiN, et al.Cryopreservation of adipose-derived mesenchymal stem cells. Cell Med, 2015; 8:3–7.
ZhuM, Heydarkhan-HagvallS, HedrickM, et al.Manual isolation of adipose-derived stem cells from human lipoaspirates. J Vis Exp, 2013; e50585.
23.
IyerM, WuL, CareyM, et al.Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A, 2001; 98:14595–14600.
24.
BougioukliS, SugiyamaO, PannellW, et al.Gene therapy for bone repair using human cells: superior osteogenic potential of BMP-2 transduced mesenchymal stem cells derived from adipose tissue compared to bone marrow. Hum Gene Ther, 2018; 29:507–519.
25.
GruberHE, SomayajiS, RileyF, et al.Human adipose-derived mesenchymal stem cells: serial passaging, doubling time and cell senescence. Biotech Histochem, 2012; 87:303–311.
26.
DominiciM, Le BlancK, MuellerI, et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006; 8:315–317.
27.
GregoryCA, GunnWG, PeisterA, et al.An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem, 2004; 329:77–84.
28.
MoseleyTA, ZhuM, HedrickMH. Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg, 2006; 118:121S–128S.
29.
BaltzerAWA, LiebermanJR. Regional gene therapy to enhance bone repair. Gene Ther, 2004; 11:344–350.
30.
ZanataF, ShaikS, DevireddyRV, et al.Cryopreserved adipose tissue-derived stromal/stem cells: potential for applications in clinic and therapy. Adv Exp Med Biol, 2016; 951:137–146.
31.
MazurP.Freezing of living cells: mechanisms and implications. Am J Physiol, 1984; 247:C125–142.
32.
ThirumalaS, ZvonicS, FloydE, et al.Effect of various freezing parameters on the immediate post-thaw membrane integrity of adipose tissue derived adult stem cells. Biotechnol Prog, 2005; 21:1511–1524.
33.
DetryG, CalvetL, StraetmansN, et al.Impact of uncontrolled freezing and long-term storage of peripheral blood stem cells at −80°C on haematopoietic recovery after autologous transplantation. Report from two centres. Bone Marrow Transplant, 2014; 49:780–785.
34.
LisenkoK, PavelP, KriegsmannM, et al.Storage duration of autologous stem cell preparations has no impact on hematopoietic recovery after transplantation. Biol Blood Marrow Transplant, 2017; 23:684–690.
35.
PollockK, SamsonrajRM, DudakovicA, et al.Improved post-thaw function and epigenetic changes in mesenchymal stromal cells cryopreserved using multicomponent osmolyte solutions. Stem Cells Dev, 2017; 26:828–842.
36.
De RosaA, De FrancescoF, TirinoV, et al.A new method for cryopreserving adipose-derived stem cells: an attractive and suitable large-scale and long-term cell banking technology. Tissue Eng Part C Methods, 2009; 15:659–667.
37.
DevireddyRV, ThirumalaS, GimbleJM. Cellular response of adipose derived passage-4 adult stem cells to freezing stress. J Biomech Eng, 2005; 127:1081–1086.
38.
LecchiL, GiovanelliS, GagliardiB, et al.An update on methods for cryopreservation and thawing of hemopoietic stem cells. Transfus Apher Sci, 2016; 54:324–336.
39.
GondaK, ShigeuraT, SatoT, et al.Preserved proliferative capacity and multipotency of human adipose-derived stem cells after long-term cryopreservation. Plast Reconstr Surg, 2008; 121:401–410.
40.
ShaikS, WuX, GimbleJ, et al.Effects of decade long freezing storage on adipose derived stem cells functionality. Sci Rep, 2018; 8:8162.
41.
CoopmanK, MedcalfN.From production to patient: challenges and approaches for delivering cell therapies. In: StemBook [Internet]. Cambridge, MA: Harvard Stem Cell Institute. www.ncbi.nlm.nih.gov/books/NBK208660/ (last accessed April16, 2018).
42.
MendicinoM, BaileyAM, WonnacottK, et al.MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell, 2014; 14:141–145.
43.
HarrisJD, SistonRA, PanX, et al.Autologous chondrocyte implantation: a systematic review. J Bone Joint Surg Am, 2010; 92:2220–2233.
44.
PareekA, CareyJL, ReardonPJ, et al.Long-term outcomes after autologous chondrocyte implantation: a systematic review at mean follow-up of 11.4 years. Cartilage, 2016; 7:298–308.
45.
SuhLH, ZhangC, ChuckRS, et al.Cryopreservation and lentiviral-mediated genetic modification of human primary cultured corneal endothelial cells. Invest Ophthalmol Vis Sci, 2007; 48:3056–3061.
46.
GülenD, MaasS, JuliusH, et al.Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical use. Int Immunopharmacol, 2012; 13:61–68.
47.
LiZH, BroxmeyerHE, LuL. Cryopreserved cord blood myeloid progenitor cells can serve as targets for retroviral-mediated gene transduction and gene-transduced progenitors can be cryopreserved and recovered. Leukemia, 1995; 9:S12–16.
48.
YongKW, Pingguan-MurphyB, XuF, et al.Phenotypic and functional characterization of long-term cryopreserved human adipose-derived stem cells. Sci Rep, 2015; 5:9596.
49.
ThirumalaS, GimbleJM, DevireddyRV. Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells. Stem Cells Dev, 2010; 19:513–522.
50.
JamesAW, LeviB, NelsonER, et al.Deleterious effects of freezing on osteogenic differentiation of human adipose-derived stromal cells in vitro and in vivo. Stem Cells Dev, 2011; 20:427–439.
51.
WindrumP, MorrisTCM, DrakeMB, et al.Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant, 2005; 36:601–603.
52.
BenekliM, AndersonB, WentlingD, et al.Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplant, 2000; 25:1299–1301.
53.
WindrumP, MorrisTCM. Severe neurotoxicity because of dimethyl sulphoxide following peripheral blood stem cell transplantation. Bone Marrow Transplant, 2003; 31:315.
